Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Konstantinos Sfaelos has a total of 78 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Using Conjoint Analysis to Elicit Benefit–Risk Preferences for Different Treatment Options Among Psoriasis Patients Receiving Systemic Therapy

    by Antonios Tsartsarakis, Eleftheria Tampouratzi, Christos Moulias, Konstantinos Sfaelos, Vassilis Aletras

    Background: Psoriasis has a huge impact on a patient’s life. Treatment dissatisfaction and non-adherence are common among patients with psoriasis, partly due to discordance between individual preferences and recommended treatments. The modern strategy for psoriasis should be focused on human-centric treatment that recognizes the needs and preferences of patients with a goal for safe, effective, quality and acceptable health services for a lifetime. The aim of this analysis was to capture patients’ preferences with moderate-to-severe psoriasis regarding various treatment attributes. Methods: A specialized questionnaire containing four attributes with three levels, each, was used, followed by an orthogonal plan based on conjoint analysis. Nine combinations of therapeutic scenarios were produced as a result, to investigate participants’ preferences. Respondents were asked to rank alternatives from best to worst. Results: The risk of developing pneumonia or other serious infections within a decade seems to be higher in patients with an implied assigned value of 37. The second attribute was the type and frequency of the administration with a value of 27, followed by the treatment effectiveness with great improvement of body surface with a value of 25. The lowest utility (11) was the sustainability of early remission of psoriasis. Conclusions: Psoriasis patients want safe, effective and easy to administer treatments.

  • Open Access

    Using Conjoint Analysis to Elicit Benefit-Risk Preferences for Different Treatment Options Among Psoriasis Patients Receiving Systemic Treatment

    by Antonios Tsartsarakis, Eleftheria Tampouratzi, Christos Moulias, Konstantinos Sfaelos, Vasilios Aletras

    Background: Psoriasis has a huge impact on patient’s life. Treatment dissatisfaction and non-adherence are common among patients with psoriasis, partly due to discord-ance between individual preferences and recommended treatments. The modern strategy for psoriasis should be focused on human centric treatment that recognizes the needs and preferences of patients with a goal for safe, effective, quality, and ac-ceptable health services for a lifetime. The aim of this analysis was to capture patients’ preferences with moderate-to-severe psoriasis regarding various treatment attributes. Methods: Development of a specialized questionnaire containing four attributes with three levels each was used, followed by an orthogonal plan based on conjoint analysis. Nine combinations of therapeutic scenarios were produced as a result, to investigate participants’ preferences. Respondents were asked to rank alternatives from best to worst. Results: The risk of developing pneumonia or other serious infection within a decade, seems to affect more the overall preference of patients with an implied assigned value of 37. The second attribute was the type and frequency of the administration with a value of 27 followed by the treatment effectiveness with great improvement of body surface with a value of 25. The lowest utility (11) was sustainability of long-term re-mission of psoriasis. Conclusions: Psoriasis patients want safe, effective, and easy to administer treatments.

  • Open Access

    The Neutrophil-to-Lymphocyte Ratio as a Prognostic Biomarker of Fournier’s Gangrene Severity: A Meta-Analysis

    by Konstantinos Seretis, Nikolaos Bounas, Konstantinos Sfaelos, Georgios Gaitanis, Ioannis Bassukas

    Background/Objectives: Fournier’s Gangrene (FG) is a severe and potentially fatal necrotizing infection of the perianal and genital regions, which necessitates prompt therapeutic interventions to prevent disease progression. Accruing evidence from recent research indicates that the neutrophil‒to-lymphocyte ratio (NLR) can predict clinical severity and mortality risk in patients with critical illnesses across various etiologies. This meta-analysis aimed to assess the efficacy of NLR as a prognostic indicator for mortality in patients with FG. Methods: An electronic literature search was conducted across several databases from their inception to 31 May 2024, following a predetermined protocol. Study quality was evaluated using the Cochrane risk of bias tool. A random-effect model was utilized to synthesize the available data. Results: Twelve studies reporting on 767 patients were included in the meta-analysis. Higher NLR levels at presentation were recorded in non-survivors than in survivors (MD = 4.49 [95% CI: 0.67–8.32]; p = 0.02). A 76% increased mortality risk was detected for patients with an NLR ≥ 8 (1.76 RR [1.35–2.3], p = 0.0001), and the mortality risk was more than twofold greater for patients with an NLR ≥ 10 compared to the remaining patients (RR = 2.31 [1.27–4.21], p = 0.006). All included studies exhibited a moderate to serious risk of bias. Conclusions: This meta-analysis reveals that the NLR represents a promising biomarker that can serve as a prognostic indicator in patients with FG. Future studies should address the establishment of proper disease-specific cutoff values to aid in clinical decision-making.


  • Open Access

    The Neutrophil-to-Lymphocyte Ratio as a Biomarker in Cutaneous Oncology: A Systematic Review of Evidence beyond Malignant Melanoma

    by Konstantinos Seretis, Konstantinos Sfaelos, Elena Boptsi, Georgios Gaitanis, Ioannis D. Bassukas

    With the ongoing progress of basic research along with the introduction of new pharmaceutical options spanning almost all therapeutic areas, the need for biomarkers that will be implemented into the personalized medical approach is higher than ever. Their use can be incorporated into clinical practice and can be applied to the classification of disorders and the evaluation of disease severity but also to the monitoring of the progress of therapeutic/pharmaceutical interventions. This systematic review collects the findings of hematologic biomarkers in various cutaneous malignancies, excluding malignant melanoma, to support their potential use in the prognosis but also in the assessment of therapeutic strategies for the specific category of skin disorders.


  • Real‐world data on the effectiveness of brodalumab in patients with moderate‐to severe plaque psoriasis in the Greek clinical setting (the BrIDGE study)

    by Dimitrios Rigopoulos, Eleftheria Tampouratzi, Charalampos Angelakopoulos, Zoe Apalla, Ioannis Barkis, Sophia Georgiou, Florentina Delli, Alexandros Drosos, Efterpi Zafiriou, John Katsantonis, et al.

    Background: Despite that brodalumab's efficacy and safety have been assessed in randomized clinical trials, real‐life data remain scarce. BrIDGE was an observational, prospective, single‐cohort, multicentre study that recruited patients with moderate‐to severe plaque psoriasis in Greece.Objectives: The primary objective was to assess the proportion of patients who achieved Psoriasis Area and Severity Index (PASI)100 after 24 weeks. Other endpoints included: the maintenance of PASI90/100 through to 104 weeks, the short‐term response [PASI75/90/100 and static Physician's Global Assessment (sPGA) 0/1] to brodalumab at 12–16 weeks and time to complete clearance. Moreover, we explored the change in quality of life [Dermatology Life Quality Index (DLQI) 0/1] and adherence to brodalumab.Methods: Two hundred patients who were initiating treatment with or switching to brodalumab, were recruited. Analyses were conducted using the as observed data and three imputation approaches were also applied for the missing data (last observation carried forward, ‘worst case’ and ‘best case’ scenario). Continuous variables were reported using summary statistics, whereas categorical variables were reported in frequency tables.Results: Based on the ‘as observed data’, 42.0% of patients achieved PASI100 at Week 24 after 25.9 ± 3.5 weeks and 65% of patients attained PASI100 at Week 104. In total, 70.2%, 47.5% and 32.0% achieved PASI75/90/100, respectively, whereas 72.6% of patients achieved sPGA 0/1, at Weeks 12–16. With respect to sPGA status 82.8%, 89.2% and 92.5% of patients achieved sPGA 0/1 at Weeks 24, 52 and 104, respectively. The time to achieve PASI100 at Weeks 12–16 was 13.7 ± 1.3, 52.1 ± 3.4 weeks at Week 52 and 105.5 ± 4.8 weeks at Week 104. Mean DLQI and Psoriasis Symptom Inventory (PSI) scores decreased by 11.4 ± 7.0 and 15.4 ± 6.5 points from baseline to Week 104, respectively. Adherence to treatment was equal to 98.9%.Conclusions: Brodalumab confers rapid and durable responses, as well as improvements in the quality of life of moderate‐to‐severe psoriasis patients.


  • Profil du brodalumab pour le traitement du psoriasis en plaques modéré à sévère dans la pratique clinique quotidienne grecque : résultats de l’étude BrIDGE

    by A. Khemis, D. Ioannides, D. Rigopoulos, E. Papadavid, E. Lazaridou, E. Zafeiriou, S. Georgiou, F. Delli, M. Papakonstantis, E. Tampouratzi, et al.

  • Open Access

    Translation and validation of patient-oriented eczema measure in the Greek language

    by Garyfallia Stefanou, Stamatios Gregoriou, Mihalis Bakakis, Styliani Mastraftsi, Alexandros Stratigos, Stathis Kontodimas, Konstantinos Sfaelos, Georgia Kourlaba

    Translating and validating the Greek version of the Patient Oriented Eczema Measure (POEM) was our goal. A parallel backtranslation process was used to translate POEM. A total of fiftynine adult atopic dermatitis patients were enlisted to assess validity and reliability. Through patient interviews with physicians, a questionnaire comprising demographics, POEM, and the dermatology life quality index (DLQI) was filled out. 3-7 days after the first visit, a second POEM completion was conducted. The POEM items conducted with study participants demonstrated a good level of internal consistency (Cronbach’s alpha = 0.88), and no overall floor and ceiling effects were found. There was a significant correlation between the DLQI and POEM scores (Spearman rho =0.71; p<0.001). The POEM score between interviews showed an average intraclass correlation coefficient (95% confidence interval) of 0.89 (0.80, 0.94), indicating good to excellent test-retest reliability. Patient-reported outcome measures are becoming more and more common in Greece, so it’s critical to have access to Greek translations of validated instruments that are frequently used in literature.


  • 41662 Brodalumab’s profile for the treatment of patients with moderate-to-severe plaque psoriasis in the Greek everyday clinical practice: Results of the BrIDGE study

    by Pantelis Panagakis, Dimitrios Ioannides, Dimitrios Rigopoulos, Evangelia Papadavid, Elisavet Lazaridou, Efterpi Zafeiriou, Sophia Georgiou, Florentina Delli, Markos Papakonstantis, Eleftheria Tampouratzi, et al.

  • Open Access

    Patient Engagement With the Myderma Platform for Psoriasis During the COVID-19 Pandemic

    by Konstantinos Sfaelos, Stathis Kontodimas, Theodora Charisiadi, Nagia Chantzara, George Pesiridis, Eleftheria Tampouratzi

  • Open Access

    Preoperative and postoperative evaluation of survivin in peripheral blood of patients with non-melanoma skin cancers. A pilot study

    by Eleftheria Tampouratzi, Konstantinos Asonitis, John Katsantonis, Kyriakos Talaiporou, Konstantinos Sfaelos

    To evaluate the preoperative and postoperative survivin [an apoptosis inhibitor (IAP) protein] peripheral blood levels and C-Reactive Protein (CRP), in patients with basal cell carcinoma (BCC) and ...